CINCINNATI--(BUSINESS WIRE)--Camargo Pharmaceutical Services, the leading global drug development strategist specializing in the 505(b)(2) approval pathway, has appointed Marc Wiles, Ph.D., as vice president, scientific and regulatory affairs, and Suzanne Beck, J.D., M.P.H., as director, contracts and legal projects.
With more than 20 years of experience in drug development, Wiles brings extensive technical and regulatory expertise to Camargo in assessing, developing and registering therapeutic products. He has demonstrated success across the full life cycle of pharmaceutical product research, development and regulatory affairs in Europe and the United States, with considerable interaction with regulatory agencies.
“Marc has demonstrated the ability to develop and execute regulatory and scientific strategies, and his skills and experiences will be hugely beneficial to our clients and our internal teams,” said Ken Phelps, Camargo president and CEO.
Before joining Camargo, Wiles was general manager and regulatory affairs scientific advisor at NDA Regulatory Science in England, where he was responsible for expanding the company’s U.S. operations. Wiles was also director of regulatory affairs (nonclinical and clinical) and general manager at ERA Consulting and senior vice president of operations at ProImmune.
Beck brings vast legal and regulatory experience to Camargo having served as an attorney for more than 15 years, including 10 years as a pharmaceutical document review attorney working across all phases of product development as well as pre- and post-marketing and FDA regulatory filings.
“Suzanne is a great addition to Camargo,” said Jim Beach, Camargo chief operating officer. “Her experience and talent as an attorney and her extensive regulatory background make her a valued asset to our team and our clients’ development programs.”
About Camargo Pharmaceutical Services
Camargo Pharmaceutical Services is the most experienced global strategist providing comprehensive drug development services specialized for the 505(b)(2) approval pathway and global equivalent processes. By assessing the scientific, medical, regulatory and commercial viability of product development opportunities, Camargo systematically builds and executes robust development plans that align with business strategies and ensure FDA buy-in every step of the way. Routinely holding three to six pre-IND meetings a month, Camargo works with product developers across more than 25 countries. Connect with Camargo on LinkedIn, read the company blog and visit camargopharma.com for more information.